Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3” | Zendy

Babak Sayad | Zendy; Fatemeh Norooznezhad | Zendy; Alireza Farokhi | Zendy

Open Access

Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

Author(s) -

Babak Sayad,

Fatemeh Norooznezhad,

Alireza Farokhi

Publication year - 2017

Publication title -

hepatitis monthly

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.264

H-Index - 37

eISSN - 1735-3408

pISSN - 1735-143X

DOI - 10.5812/hepatmon.46588

Subject(s) - daclatasvir , sofosbuvir , medicine , ribavirin , cirrhosis , kowsar , hepatitis c , gastroenterology , genotype , virology , chronic hepatitis , virus , gene , biochemistry , chemistry

Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3” Babak Sayad, Fatemeh Norooznezhad, and Alireza Farokhi Liver Diseases Research Center, Kermanshah University of Medical Sciences, Iran Corresponding author: Babak Sayad, Liver Diseases Research Center, Kermanshah University of Medical Sciences, Iran, E-mail: babaksayad@yahoo.com

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research